Literature DB >> 10598790

Characterisation of human recombinant somatostatin receptors. 3. Modulation of adenylate cyclase activity.

S Siehler1, D Hoyer.   

Abstract

The five human somatostatin receptor subtypes (hsst1-5) were stably expressed in CCL39 cells (Chinese hamster lung fibroblast cells) to study the inhibition of forskolin-stimulated adenylate cyclase (FSAC) activity induced by somatostatin (somatotropin release inhibiting factor, SRIF), cortistatin (CST) and SRIF peptide analogues. Inhibition of FSAC was observed with all five receptors, although the maximal effects produced by SRIF14 varied from around 40% (sst1, sst2, sst4) to 67% (sst3, sst5) reflecting to some extent differences in receptor density (Bmax values published in accompanying paper, this journal). SRIF28 was slightly more potent than SRIF14 to inhibit FSAC at all five receptors, although the potency of the natural peptides SRIF14, SRIF28 and CST17 was generally similar with pEC50-values ranging from 7.5 to 8.7 depending on receptor and peptide. At SRIF1 receptors (sst2, sst3, sst5) most of the peptide analogues displayed full agonism (with some exceptions e.g. BIM 23056 at sst1-3 and sst5 receptors, and L362,855 and cycloantagonist SA at sst3 receptors), whereas at SRIF2 receptors these analogues tended to behave as partial agonists. BIM 23056 was an antagonist at sst3 receptors (antagonist binding constant pKB = 6.33), but not at other receptors. The AC inhibition profiles of sst1-5 receptors were compared with the different radioligand binding profiles as well as with [35S]guanosine 5'-O-(3-thiotriphosphate) ([35S]GTPgammaS) binding profile for sst2-5 receptors. High correlations were observed between FSAC inhibition, radioligand binding and [35S]GTPgammaS binding profiles at sst3, sst4 and sst5 receptors; by contrast, correlation coefficients at sst1 and sst2 receptors were low, and the binding profiles of [125I][Tyr10]CST14 correlated poorly. In line with these findings, the FSAC inhibition and [35S]GTPgammaS binding correlated poorly at sst2 receptors (sst1 receptors show no significant induction of [35S]GTPgammaS binding). The apparent lack of, or only weak, relationship between FSAC, radioligand or [35S]GTPgammaS binding observed for some SRIF receptors suggests that different active states may exist for these receptors, which may favour one transduction cascade over others.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598790     DOI: 10.1007/s002109900143

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  10 in total

1.  Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Dominique Fehlmann; Daniel Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

2.  Comparison of functional profiles at human recombinant somatostatin sst2 receptor: simultaneous determination of intracellular Ca2+ and luciferase expression in CHO-K1 cells.

Authors:  Caroline Nunn; Davide Cervia; Daniel Langenegger; Laurent Tenaillon; Rochdi Bouhelal; Daniel Hoyer
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

3.  VeloceGenomics: an accelerated in vivo drug discovery approach to rapidly predict the biologic, drug-like activity of compounds, proteins, or genes.

Authors:  Ruben Papoian; Andreas Scherer; Muriel Saulnier; Frank Staedtler; André Cordier; Francois Legay; Gerard Maurer; Joerg Staeheli; Jacky Vonderscher; Salah-Dine Chibout
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

Review 4.  Selective agonism in somatostatin receptor signaling and regulation.

Authors:  Agnes Schonbrunn
Journal:  Mol Cell Endocrinol       Date:  2007-10-07       Impact factor: 4.102

5.  Somatostatin potentiates NMDA receptor function via activation of InsP(3) receptors and PKC leading to removal of the Mg(2+) block without depolarization.

Authors:  A Pittaluga; A Bonfanti; M Raiteri
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

Review 6.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 7.  Drug design at peptide receptors: somatostatin receptor ligands.

Authors:  Jason P Hannon; Caroline Nunn; Barbara Stolz; Christians Bruns; Gisbert Weckbecker; Ian Lewis; Thomas Troxler; Konstanze Hurth; Daniel Hoyer
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

8.  Somatostatin inhibits potassium-evoked glutamate release by activation of the sst(2) somatostatin receptor in the mouse retina.

Authors:  Massimo Dal Monte; Cristina Petrucci; Andrea Cozzi; Jeremy P Allen; Paola Bagnoli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-14       Impact factor: 3.000

9.  Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer.

Authors:  Cheng-Zhi Qiu; Chuan Wang; Zhong-Xin Huang; Shi-Ze Zhu; You-Yi Wu; Jian-Long Qiu
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

10.  A functional comparison of recombinant and native somatostatin sst2 receptor variants in epithelia.

Authors:  N D Holliday; I R Tough; H M Cox
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.